SLC38A5 promotes glutamine metabolism and inhibits cisplatin chemosensitivity in breast cancer
CONCLUSION: Our findings suggest that SLC38A5 enhances BC cell viability by glutamine metabolism, inhibits the chemical sensitivity of cisplatin in BC cells, and promotes tumor growth, emphasizing the clinical relevance of SLC38A5 in BC management as a novel potential therapeutic target.PMID:37914960 | DOI:10.1007/s12282-023-01516-8 (Source: Breast Cancer)
Source: Breast Cancer - November 2, 2023 Category: Cancer & Oncology Authors: Xiaowei Shen Ganggang Wang Hua He Ping Shang Bin Yan Xiaoliang Wang Weixing Shen Source Type: research
SLC38A5 promotes glutamine metabolism and inhibits cisplatin chemosensitivity in breast cancer
CONCLUSION: Our findings suggest that SLC38A5 enhances BC cell viability by glutamine metabolism, inhibits the chemical sensitivity of cisplatin in BC cells, and promotes tumor growth, emphasizing the clinical relevance of SLC38A5 in BC management as a novel potential therapeutic target.PMID:37914960 | DOI:10.1007/s12282-023-01516-8 (Source: Breast Cancer)
Source: Breast Cancer - November 2, 2023 Category: Cancer & Oncology Authors: Xiaowei Shen Ganggang Wang Hua He Ping Shang Bin Yan Xiaoliang Wang Weixing Shen Source Type: research
Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy
CONCLUSION: Our models predicted greater reductions in the occurrence of relapsed mBC with adjuvant T-DM1 vs trastuzumab in the indicated populations in EU5 and Canada. Introduction of T-DM1 has the potential to reduce population-level disease burden of HER2-positive mBC in the geographies studied.PMID:37907759 | DOI:10.1007/s12282-023-01514-w (Source: Breast Cancer)
Source: Breast Cancer - November 1, 2023 Category: Cancer & Oncology Authors: Mellissa Williamson David J Press Svenn Alexander Hansen Akanksha Tomar Gurleen Singh Jhuti Cedric Revil Kaustubh Gururaj Source Type: research
Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy
CONCLUSION: Our models predicted greater reductions in the occurrence of relapsed mBC with adjuvant T-DM1 vs trastuzumab in the indicated populations in EU5 and Canada. Introduction of T-DM1 has the potential to reduce population-level disease burden of HER2-positive mBC in the geographies studied.PMID:37907759 | DOI:10.1007/s12282-023-01514-w (Source: Breast Cancer)
Source: Breast Cancer - November 1, 2023 Category: Cancer & Oncology Authors: Mellissa Williamson David J Press Svenn Alexander Hansen Akanksha Tomar Gurleen Singh Jhuti Cedric Revil Kaustubh Gururaj Source Type: research
Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole
CONCLUSIONS: In this population of Japanese women with ER+/HER2- ABC, median OS was over 7 years with 1L PAL + LET, supporting the use of 1L PAL + endocrine therapy.TRIAL NUMBER: NCT04735367.PMID:37882974 | DOI:10.1007/s12282-023-01511-z (Source: Breast Cancer)
Source: Breast Cancer - October 26, 2023 Category: Cancer & Oncology Authors: Masato Takahashi Tomofumi Osako Hiroyuki Yasojima Kenichi Inoue Masahiro Kawashima Hideki Maeda Akemi Ichikawa Yasuaki Muramatsu Norikazu Masuda Source Type: research
Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole
CONCLUSIONS: In this population of Japanese women with ER+/HER2- ABC, median OS was over 7 years with 1L PAL + LET, supporting the use of 1L PAL + endocrine therapy.TRIAL NUMBER: NCT04735367.PMID:37882974 | DOI:10.1007/s12282-023-01511-z (Source: Breast Cancer)
Source: Breast Cancer - October 26, 2023 Category: Cancer & Oncology Authors: Masato Takahashi Tomofumi Osako Hiroyuki Yasojima Kenichi Inoue Masahiro Kawashima Hideki Maeda Akemi Ichikawa Yasuaki Muramatsu Norikazu Masuda Source Type: research
Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole
CONCLUSIONS: In this population of Japanese women with ER+/HER2- ABC, median OS was over 7 years with 1L PAL + LET, supporting the use of 1L PAL + endocrine therapy.TRIAL NUMBER: NCT04735367.PMID:37882974 | DOI:10.1007/s12282-023-01511-z (Source: Breast Cancer)
Source: Breast Cancer - October 26, 2023 Category: Cancer & Oncology Authors: Masato Takahashi Tomofumi Osako Hiroyuki Yasojima Kenichi Inoue Masahiro Kawashima Hideki Maeda Akemi Ichikawa Yasuaki Muramatsu Norikazu Masuda Source Type: research
Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole
CONCLUSIONS: In this population of Japanese women with ER+/HER2- ABC, median OS was over 7 years with 1L PAL + LET, supporting the use of 1L PAL + endocrine therapy.TRIAL NUMBER: NCT04735367.PMID:37882974 | DOI:10.1007/s12282-023-01511-z (Source: Breast Cancer)
Source: Breast Cancer - October 26, 2023 Category: Cancer & Oncology Authors: Masato Takahashi Tomofumi Osako Hiroyuki Yasojima Kenichi Inoue Masahiro Kawashima Hideki Maeda Akemi Ichikawa Yasuaki Muramatsu Norikazu Masuda Source Type: research
Overall survival in Japanese patients with ER+/HER2- advanced breast cancer treated with first-line palbociclib plus letrozole
CONCLUSIONS: In this population of Japanese women with ER+/HER2- ABC, median OS was over 7 years with 1L PAL + LET, supporting the use of 1L PAL + endocrine therapy.TRIAL NUMBER: NCT04735367.PMID:37882974 | DOI:10.1007/s12282-023-01511-z (Source: Breast Cancer)
Source: Breast Cancer - October 26, 2023 Category: Cancer & Oncology Authors: Masato Takahashi Tomofumi Osako Hiroyuki Yasojima Kenichi Inoue Masahiro Kawashima Hideki Maeda Akemi Ichikawa Yasuaki Muramatsu Norikazu Masuda Source Type: research
Feasibility of accelerated partial breast irradiation with strut-adjusted volume implant brachytherapy in Japan focusing on dosimetry and acute toxicity: a Japanese multi-institutional prospective study
CONCLUSION: APBI with SAVI brachytherapy is feasible in Japan from the aspects of compliance with dose constraints and frequency of acute toxicities.PMID:37865624 | DOI:10.1007/s12282-023-01513-x (Source: Breast Cancer)
Source: Breast Cancer - October 21, 2023 Category: Cancer & Oncology Authors: Masahiro Yoshida Ryo-Ichi Yoshimura Ryoichi Notake Hidenori Shinjo Kazunori Miyaura Takashi Kuwayama Takashi Kawanaka Tadahiko Shien Kotaro Yoshio Toshiko Shiga Yuko Kaneyasu Tsuyoshi Nakagawa Kazunori Kubota Seigo Nakamura Jun Itami Working group of APBI Source Type: research
Feasibility of accelerated partial breast irradiation with strut-adjusted volume implant brachytherapy in Japan focusing on dosimetry and acute toxicity: a Japanese multi-institutional prospective study
CONCLUSION: APBI with SAVI brachytherapy is feasible in Japan from the aspects of compliance with dose constraints and frequency of acute toxicities.PMID:37865624 | DOI:10.1007/s12282-023-01513-x (Source: Breast Cancer)
Source: Breast Cancer - October 21, 2023 Category: Cancer & Oncology Authors: Masahiro Yoshida Ryo-Ichi Yoshimura Ryoichi Notake Hidenori Shinjo Kazunori Miyaura Takashi Kuwayama Takashi Kawanaka Tadahiko Shien Kotaro Yoshio Toshiko Shiga Yuko Kaneyasu Tsuyoshi Nakagawa Kazunori Kubota Seigo Nakamura Jun Itami Working group of APBI Source Type: research
Feasibility of accelerated partial breast irradiation with strut-adjusted volume implant brachytherapy in Japan focusing on dosimetry and acute toxicity: a Japanese multi-institutional prospective study
CONCLUSION: APBI with SAVI brachytherapy is feasible in Japan from the aspects of compliance with dose constraints and frequency of acute toxicities.PMID:37865624 | DOI:10.1007/s12282-023-01513-x (Source: Breast Cancer)
Source: Breast Cancer - October 21, 2023 Category: Cancer & Oncology Authors: Masahiro Yoshida Ryo-Ichi Yoshimura Ryoichi Notake Hidenori Shinjo Kazunori Miyaura Takashi Kuwayama Takashi Kawanaka Tadahiko Shien Kotaro Yoshio Toshiko Shiga Yuko Kaneyasu Tsuyoshi Nakagawa Kazunori Kubota Seigo Nakamura Jun Itami Working group of APBI Source Type: research
Feasibility of accelerated partial breast irradiation with strut-adjusted volume implant brachytherapy in Japan focusing on dosimetry and acute toxicity: a Japanese multi-institutional prospective study
CONCLUSION: APBI with SAVI brachytherapy is feasible in Japan from the aspects of compliance with dose constraints and frequency of acute toxicities.PMID:37865624 | DOI:10.1007/s12282-023-01513-x (Source: Breast Cancer)
Source: Breast Cancer - October 21, 2023 Category: Cancer & Oncology Authors: Masahiro Yoshida Ryo-Ichi Yoshimura Ryoichi Notake Hidenori Shinjo Kazunori Miyaura Takashi Kuwayama Takashi Kawanaka Tadahiko Shien Kotaro Yoshio Toshiko Shiga Yuko Kaneyasu Tsuyoshi Nakagawa Kazunori Kubota Seigo Nakamura Jun Itami Working group of APBI Source Type: research
The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition
Breast Cancer. 2023 Oct 16. doi: 10.1007/s12282-023-01510-0. Online ahead of print.ABSTRACTThe 2022 revision of the Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for surgical treatment of breast cancer was updated following a systematic review of the literature using the Medical Information Network Distribution Service (MINDS) procedure, which focuses on the balance of benefits and harms for various clinical questions (CQs). Experts in surgery designated by the JBCS addressed five areas: breast surgery, axillary surgery, breast reconstruction, surgical treatment for recurrent and metastatic breast canc...
Source: Breast Cancer - October 16, 2023 Category: Cancer & Oncology Authors: Takehiko Sakai Goro Kutomi Tadahiko Shien Sota Asaga Tomoyuki Aruga Makoto Ishitobi Sayaka Kuba Masataka Sawaki Kaori Terata Koichi Tomita Chikako Yamauchi Yutaka Yamamoto Hiroji Iwata Shigehira Saji Source Type: research
The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition
Breast Cancer. 2023 Oct 16. doi: 10.1007/s12282-023-01510-0. Online ahead of print.ABSTRACTThe 2022 revision of the Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for surgical treatment of breast cancer was updated following a systematic review of the literature using the Medical Information Network Distribution Service (MINDS) procedure, which focuses on the balance of benefits and harms for various clinical questions (CQs). Experts in surgery designated by the JBCS addressed five areas: breast surgery, axillary surgery, breast reconstruction, surgical treatment for recurrent and metastatic breast canc...
Source: Breast Cancer - October 16, 2023 Category: Cancer & Oncology Authors: Takehiko Sakai Goro Kutomi Tadahiko Shien Sota Asaga Tomoyuki Aruga Makoto Ishitobi Sayaka Kuba Masataka Sawaki Kaori Terata Koichi Tomita Chikako Yamauchi Yutaka Yamamoto Hiroji Iwata Shigehira Saji Source Type: research
